Yunnan Hansu Biotechnology Co., Ltd (hereinafter referred to as “Hansu “), a subsidiary of HMI Group , as the largest single shareholder of Yunnan Hempmon Pharmaceutical Co., Ltd. (hereinafter referred to as ” Hempmon”), held a groundbreaking ceremony on Feb 12th, 2019.
Hempmon as the phaseⅡof the Hansu industrialization project has settled in Airport Industrial Park New Central Yunnan. Hempmon successfully starts up the project with the supports of Yunnan government. The project covers an area of 54 acres, construction scale 58000 square meters, processing industrial hemp capacity of 2000 tons (expanded to 3000 tons), which will become one of the world’s largest industrial hemp extraction & processing enterprises.
Hempmon will independently R&D and construct a full set of production system at leading international standard level. The system includes intelligent storage system, continuous automated processing operating system, industrial preparative chromatography system etc. The completion of the production factory will implement intelligently separation, purification and mass production 13 kinds of spiritual activity cannabinoid material (CBD). At the same time, Hempmon has built a new factory, strictly in accordance with GMP standards, which boasts the best facilities in China. Hempmon owns the production conditions of injection-grade raw materials and high-end preparation products as for its Grade A clean area standard preparation production system.
In addition, Hempmon will push the following 4 aspects.work.
B. Hempmon will conduct research on high value development and utilization of industrial hemp, and develop healthy & safe series of industrial hemp products in the field of food and health care products cooperating with partners.
C. Hempmon will explore CBD biosynthesis technology for future upgrading to cope with the possible shortage of raw materials and high production costs.
D. Hempmon will build the first Asia industrial hemp museum and the industrial hemp plant factory workshop to popularize industrial hemp knowledge. That will demonstrate to the public display industrial hemp harvest their crop from the growth, maturity, and to the whole process of extraction, processing, and the application in the field of industrial hemp in biological medicine health value for all-round introduction and promotion.
Hansu CBD extract technology authorized Patent by the United States. The Patent is the first international patent for medical extraction of cannabinoid in China (METHOD FOR EXTRACTION CANNABIDIOL FROM CANNABI).Hansu CBD application for drug master document has also been approved by FDA, becoming the first Chinese manufacturer with DMF.
Hempmon expects to be completed and put into operation by the end of 2019, and the annual profit is in the hundreds of millions. Hempmon will supply a full complement of production capacity for the international market of non-toxic cannabinoids in short.
- ［Group News］HMI Group attends 19th CPhI China
- ［Group News］HMI Group was honored to invite Yang Baofeng (Academician of the Chinese Academy of Engineering) make a speech about industrial hemp application on preventing and controlling the major diseases
- ［Group News］HMI Group New Product Release Meeting Electronic Cigarette- iLAX
- ［Group News］HMI Group & CAPSTONE developed cooperation on blockchain and industrial hemp
- ［Group News］Minister of Malaysia MITI Visited HMI Group to Practice ”One Belt and One Road”the Bright Future of Hemp
- ［Group News］HMI Group Subsidiary Company Hansu Became a Shareholder of ACGT
- ［Group News］HMI Group Starts up a Global E-commerce Platform for Industrial Hemp Products with GTE & YRH Assets
- ［Group News］Peter Tan (Chairman of HMI Group) interviewed by Shanghai Securities News on the development of industrial hemp in China
- ［Group News］HMI Group & Dezhan Healthcare founded Hande Pharmaceutical
- ［Group News］Peter Tan (Chairman of HMI Group) interviewed by National Business Daily (NBD)- Fantasy and reality in China’s industrial hemp industry